These data indicate that the beneficial effects of SGLT2 inhibitors on blood pressure and renal fibrosis in CsA nephropathy are mediated by its action on sympathetic activity in line with results obtained in type 2 diabetes and obesity, characterized by sympathetic overactivity [42]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.